Compare iShares Core MSCI EAFE ETF (IEFA) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares Core MSCI EAFE ETF trades at $95.53 (market cap $188.94B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: iShares Core MSCI EAFE ETF is far larger — about 193.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and iShares Core MSCI EAFE ETF is more actively traded (6,200,262 versus 2,742,564). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IEFA | MRVI | |
|---|---|---|
Market Cap | $188.94B | $977.37M |
Volume | 6,200,262 | 2,742,564 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $9.00 |
52-Week Low | $85.06 | $2.83 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.64, up 0.48% on the day, while technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF provides exposure to developed markets outside North America, managing $196 billion in assets. Recent news highlights its size advantage and higher dividend yield compared to peers, though some competitors have shown stronger recent returns.
The outlook for IEFA is mixed, with bearish technicals offset by its low-cost, diversified international exposure. Opportunities include defensive shifts in investor flows away from concentrated U.S. tech, while risks involve underperformance versus broader global funds and capped upside in strategies like covered calls on the ETF.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
